Christopher Jon Forlenza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher Jon Forlenza has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Lisa Giulino-Roth
Pediatric Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA
22 shared publications - Alexandra E. Kovach
Departments of Laboratory Medicine and Pathology, Boston Children’s Hospital , Boston, MA
21 shared publications - Andriy Derkach
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
21 shared publications - Bachisio Ziccheddu
Sheila and David Fuente Cancer Biology Graduate Program, University of Miami Miller School of Medicine, Miami, Florida
21 shared publications - Bhavneet Bhinder
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
21 shared publications - Craig H. Moskowitz
Department of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL
21 shared publications
Latest Publications
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T‐Cell Lymphoblastic Leukemia/Lymphoma
Background: Relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia/lymphoma (T‐ALL/T‐LL) remains a therapeutic challenge. Allogeneic hematopoietic stem cell transplantation (HSCT) after achieving complete remission (CR) offers the only chance of cure, but effective modalities to achieve CR are limited. Activation of mTOR and PI3K pathways has been well described in T‐ALL and monotherapy with mTOR inhibitors has shown efficacy signals used in relapsed disease. Methods: This multisite Phase 1 study evaluated the safety, tolerability, and anti‐leukemic activity of everolimus with NEC chemotherapy (nelarabine, etoposide, and cyclophosphamide) among children and young adults with relapsed/refractory T‐ALL/T‐LL. Results: Eight patients were enrolled to two dose levels (DLs) on this study and no dose‐limiting toxicities were reported. Most adverse events related to therapy were expected and hematological. DL2 ( n = 5) of everolimus at 5 mg/m 2 /day was the highest dose tested. The overall response rate (complete response + complete response with incomplete platelet recovery + partial response) was 75% (6/8) with 100% (5/5) responses in the T‐ALL cohort and 33% (1/3) responses in T‐LL cohort. All six patients who obtained a PR or greater proceeded to receive HSCT as consolidation therapy. Two of the six patients transplanted are alive today with two deaths related to progressive disease and two related to veno‐occlusive disease post transplantation. Conclusions: This study demonstrates safety with a combination of everolimus and NEC chemotherapy. Given the observed tolerability and efficacy of everolimus with NEC in this small cohort of patients, this combination should be further evaluated in larger phase 2/3 clinical trials. Trial Registration: ClinicalTrials.gov identifier: NCT03328104
- 10 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (11)
ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T‐Cell Lymphoblastic Leukemia/Lymphoma
Background: Relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia/lymphoma (T‐ALL/T‐LL) remains a therapeutic challenge. Allogeneic hematopoietic stem cell transplantation (HSCT) after achieving complete remission (CR) offers the only chance of cure, but effective modalities to achieve CR are limited. Activation of mTOR and PI3K pathways has been well described in T‐ALL and monotherapy with mTOR inhibitors has shown efficacy signals used in relapsed disease. Methods: This multisite Phase 1 study evaluated the safety, tolerability, and anti‐leukemic activity of everolimus with NEC chemotherapy (nelarabine, etoposide, and cyclophosphamide) among children and young adults with relapsed/refractory T‐ALL/T‐LL. Results: Eight patients were enrolled to two dose levels (DLs) on this study and no dose‐limiting toxicities were reported. Most adverse events related to therapy were expected and hematological. DL2 ( n = 5) of everolimus at 5 mg/m 2 /day was the highest dose tested. The overall response rate (complete response + complete response with incomplete platelet recovery + partial response) was 75% (6/8) with 100% (5/5) responses in the T‐ALL cohort and 33% (1/3) responses in T‐LL cohort. All six patients who obtained a PR or greater proceeded to receive HSCT as consolidation therapy. Two of the six patients transplanted are alive today with two deaths related to progressive disease and two related to veno‐occlusive disease post transplantation. Conclusions: This study demonstrates safety with a combination of everolimus and NEC chemotherapy. Given the observed tolerability and efficacy of everolimus with NEC in this small cohort of patients, this combination should be further evaluated in larger phase 2/3 clinical trials. Trial Registration: ClinicalTrials.gov identifier: NCT03328104
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis for driver mutation discovery in Hodgkin lymphoma WGS and WES.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis for driver mutation discovery in Hodgkin lymphoma WGS and WES.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
All supplementary figures S1-S17
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells
All supplementary figures S1-S17
- Open Access
- 1 August 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (8) , 1741-1745
Less may be enough: a transplant-free future for low risk relapsed Hodgkin lymphoma
Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma
- 1 August 2025
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 14 (8) , 1741-1745
Open AccessLess may be enough: a transplant-free future for low risk relapsed Hodgkin lymphoma
Less may be enough: a transplant-free future for low-risk relapsed Hodgkin lymphoma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
All supplementary figures S1-S17
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
All supplementary figures S1-S17
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
R code of our analysis clock like mutational signatures in Hodgkin lymphoma WGS and WES.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
Supplementary Tables from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells
Supplementary Tables from Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells